Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism

Djordjević, Nataša; Radmanović, Branimir; Cukic, Jelena; Baskić, Dejan; Djukić-Dejanović, Slavica; Мilоvаnоvić, Drаgаn; Aklillu, Eleni

doi:10.1080/15622975.2018.1548779

Cited by 14 publications

(10 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Namely, women and older subjects responded better to therapy. They also displayed increased adverse effects such as relatively increased BMI and extrapyramidal symptoms as evident by Djordjevic et al’s study [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials

Rehan

Siddiqui²,

Khan³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…Around 60% of Schizophrenia patients are smokers [ 21 ]. CYP1A2 is inducible by polycyclic aromatic hydrocarbons (PAHs) present in cigarette smoke leading to increased clearance and decreased plasma levels of olanzapine [ 22 ]. Smokers have 53% increased clearance of olanzapine as compared to non-smokers [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials

Rehan

Siddiqui²,

Khan³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…Unanimously accepted is a strong inducing effect of smoking on cytochrome P450 (CYP) 1A2 isoenzyme activity. Decreased blood levels of CYP1A2 substrates such as clozapine and duloxetine as well as olanzapine are well described [7][8][9][10]; these effects are attributed to the induction of CYP1A2 by polycyclic aromatic hydrocarbons [11]. Case reports of adverse reactions in terms of smoking cessation or changes in smoking habits in clozapine-treated patients highlight the clinical relevance of the smoking effects on drug disposition [12,13].…”

Section: Introductionmentioning

confidence: 99%

“…Using caffeine as probe drug, Faber and Fuhr revealed normalization from the induced state to baseline CYP1A2 activity within only 3 days after smoking cessation [15]. Moreover, evidence supports medication dose-and/or genotype-dependent patterns for the extent of the inducing effects of smoking [10,16], whereas conflicting data on the number of smoked cigarettes per day are available [17,18].…”

Section: Introductionmentioning

confidence: 99%

Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample

et al. 2020

View full text Add to dashboard Cite

Introduction Major smoking effects have been reported for a series of psychotropic agents, mainly including substrates of CYP450 1A2, although smoking may also affect alternative metabolic pathways. To our knowledge, smoking effects on paliperidone pharmacokinetics have not been assessed yet. Methods We compared plasma concentrations of paliperidone as well as dose-corrected-plasma concentrations (C/D) from a naturalistic database between smokers and nonsmokers using nonparametrical tests, such as the Mann-Whitney U-test (MWU). Additionally, we compared light and heavy smokers with nonsmokers separately. Results Comparing 55 smokers with 37 nonsmokers treated with oral paliperidone, no differences in the percentage of females, age, body weight, body mass index, and daily paliperidone dose were reported (p=0.709 for χ2, p=0.26, p=0.38, p=0.67, and p=0.8 for MWU). No differences were detected in plasma concentrations or C/D values (p=0.50 and p=0.96 for MWU). Likewise, differences in daily dose, plasma concentrations, or C/D values were not significant between light smokers (n=17) and nonsmokers (p=0.61, p=0.81, and p=0.33 for MWU) or heavy smokers (n=22) and nonsmokers (p=0.874, p=0.38, and p=0.59; MWU in all cases). Discussion Paliperidone is not affected by smoking, and paliperidone dose-adjustments in smokers may not be necessary. This may be seen as an essential difference to risperidone, whose cytochrome-mediated metabolism might be affected by smoking.

show abstract

“…Interestingly, caffeine is also metabolized by CYP1A2, and studies have found smoking increases caffeine clearance by inducing CYP1A2 activity, as it does with clozapine and olanzapine [ 42 ]. One meta-analysis found that cigarette smoking of at least five cigarettes a day and consuming more than three cups of coffee a day was associated with diminished efficacy but increased safety of olanzapine [ 43 ]. In the context of smoking cessation, it has been suggested that lowering doses of clozapine and olanzapine by 30-40% was necessary to restore serum concentrations to previously stable levels [ 44 ].…”

Section: Reviewmentioning

confidence: 99%

Cigarette Smoking and Schizophrenia: Etiology, Clinical, Pharmacological, and Treatment Implications

Ding

2021

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

Recent data suggests that the prevalence of smoking in schizophrenia remains high. While reports suggest that smoking increases the risk of developing schizophrenia, the potential causative role of smoking in this relationship needs further investigation. Smokers with schizophrenia are more likely to have more intense positive symptoms and lower cognitive function, but diminished intensity of extrapyramidal side effects than nonsmoking patients with schizophrenia. They were also more likely to exhibit aggressive behaviour compared to nonsmokers, which could suggest higher levels of baseline aggression. The significant cost associated with regular tobacco expenditure can detract from investment in key domains. Large-scale trials have shown that pharmacotherapy for smoking cessation is effective and does not worsen the risk of developing neuropsychiatric symptoms compared to placebo. Electronic cigarette use among schizophrenia patients is high, and there is emerging evidence supportive of its efficacy. Future improvements include large-scale trials assessing the utility, efficacy, and safety of electronic cigarettes in schizophrenia patients.

show abstract

Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism

Cited by 14 publications

References 60 publications

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials

Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample

Cigarette Smoking and Schizophrenia: Etiology, Clinical, Pharmacological, and Treatment Implications

Contact Info

Product

Resources

About